- Report
- February 2024
- 70 Pages
Brazil
From €4529EUR$4,750USD£3,882GBP
- Report
- February 2024
- 70 Pages
Russia
From €4529EUR$4,750USD£3,882GBP
- Report
- February 2024
- 70 Pages
Australia
From €4529EUR$4,750USD£3,882GBP
- Report
- February 2024
- 70 Pages
China
From €4529EUR$4,750USD£3,882GBP
- Report
- February 2024
- 70 Pages
Japan
From €4529EUR$4,750USD£3,882GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4529EUR$4,750USD£3,882GBP
- Report
- August 2023
- 70 Pages
South Korea
From €4529EUR$4,750USD£3,882GBP
- Report
- October 2022
- 70 Pages
Africa
From €4529EUR$4,750USD£3,882GBP
- Report
- August 2020
- 150 Pages
Global
From €4052EUR$4,250USD£3,473GBP
- Report
- October 2019
- 125 Pages
Canada
From €4529EUR$4,750USD£3,882GBP
- Report
- February 2019
- 30 Pages
Global
From €9535EUR$10,000USD£8,172GBP
- Drug Pipelines
- February 2018
- 207 Pages
Global
From €20977EUR$22,000USD£17,979GBP
- Drug Pipelines
- February 2018
- 33 Pages
Global
From €9535EUR$10,000USD£8,172GBP
- Report
- February 2021
- 90 Pages
Global
€20977EUR$22,000USD£17,979GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €477EUR$500USD£409GBP
- Report
- January 2019
- 35 Pages
Global
From €953EUR$1,000USD£817GBP
Invokana is a prescription medication used to treat type 2 diabetes, a chronic endocrine and metabolic disorder. It belongs to a class of drugs known as sodium-glucose cotransporter-2 (SGLT2) inhibitors, which work by blocking the reabsorption of glucose by the kidneys, allowing it to be eliminated in the urine. Invokana is taken orally once a day and is typically used in combination with diet and exercise to improve glycemic control. It is also used to reduce the risk of cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
Invokana is marketed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. Other companies in the market include AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk, and Sanofi. Show Less Read more
